Bristol Myers Squibb presented the positive Phase III results on its already approved Opdivo-Yervoy combo at ESMO over the ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

The first undervalued wide-moat stock on our list is Bristol Myers Squibb. The drugmaker’s portfolio covers many therapeutic ...

Battery management system (BMS) hardware and software continue to evolve as electric vehicles (EVs) transition to 800-V ...

Experts noted, however, there is insufficient evidence to determine which commercially available KRAS G12C inhibitor is the ...

“Our data at ESMO this year highlight BMS’ enduring impact in oncology and offer insights into our earlier-phase, next-generation assets,” said Samit Hirawat, M.D., executive vice ...

The FDA issued draft guidance on oncology clinical trials, taking the first steps toward formalizing a position that it's ...

Analyst Mohit Bansal from Wells Fargo maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and keeping the price ...

Bristol Myers Squibb (NYSE: BMY) has struggled to manage the loss of exclusivity now that some of its top-selling drugs are facing competition from generics. Disappointing results from the ...

Bristol Myers Squibb (NYSE: BMY) has struggled to manage ... with a portfolio of more than 30 products and an even larger clinical pipeline across fields like hematology, oncology, cardiology ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.